Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease

Abstract

The dopa analogue 6-fluorodopa (6-FD) used with positron emission tomography (PET) allows in vivo visualization of dopamine and its metabolites in nigrostriatal nerve endings1. We have now found abnormal 6-FD scans in four subjects exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). None had parkinsonism. The results suggest subclinical damage to the nigrostriatal pathway. This is the first direct evidence that dopaminergic impairment can exist without clinical deficits. Here we discuss this finding in the context of the hypothesis that Parkinson's disease may stem from clinically silent damage to the substantia nigra, followed by slow attrition of neurones in this region because of its particular vulnerability to cell loss as a normal consequence of ageing.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Garnett, E. S., Firnau, G. & Nahmias, C. Nature 305, 137–138 (1983).

    Article  ADS  CAS  PubMed  Google Scholar 

  2. Langston, J. W. & Ballard, P. Can. J. neurol. Sci. 11, 160–166 (1985).

    Article  Google Scholar 

  3. Langston, J. W. Life Sci. 36, 201–206 (1985).

    Article  CAS  PubMed  Google Scholar 

  4. Teravainen, H. T. & Calne, D. B. in Parkinson's Disease—Current Progress, Problems and Management (eds Rinne, U.K., Klinger, M. & Stamm, G.) 145–165 (Eisevier/North-Holland, Amsterdam, 1980).

    Google Scholar 

  5. Adam, M. J., Abeysekera, B., Ruth, T. J., Grierson, J. R. & Pate, B. D. J. nucl. Med. 26(5), P125 (1985).

    Google Scholar 

  6. Ter-Pogossian, M. M., Ficke, D. C., Hood, J. T., Yamamoto, M. & Mullani, N. A. J. Computer Assisted Tomography 6, 125–133 (1982).

    Article  CAS  Google Scholar 

  7. Evans, B. et al. IEEE Trans. nucl. Sci. NS-30, 707–710 (1983).

  8. Horne, M. K., Chang, C. H. & Wooten, G. F. Pharmacology 28, 12–26 (1984).

    Article  CAS  PubMed  Google Scholar 

  9. Calne, D. B. & Langston, J. W. Lancet ii, 1457–1459 (1983).

    Article  Google Scholar 

  10. Garnett, E. S., Firnau, G., Nahmias, C., Sood, S. & Belbeck, L. Am. J. Physiol. 238, R318–R327 (1980).

    CAS  PubMed  Google Scholar 

  11. Martin, W. R. W., Boyes, B. E., Leenders, K. L. & Patlak, C. S. J. cerebral Blood Flow Metab. (in the press).

  12. Lieberman, A. N. & Goldstein, M. New Engl. J. Med. 312, 509 (1985).

    CAS  PubMed  Google Scholar 

  13. Nutt, J. G., Rosin, A. J., Eisler, T., Calne, D. B. & Chase, T. N. Archs Neurol. 35, 827–830 (1978).

    Article  Google Scholar 

  14. Kushinsky, K. & Hornykiewicz, O. Eur. J. Pharmac. Vol? 41–50 (1974).

  15. Langston, J. W. in Recent Advances in Parkinson's Disease (eds Fahn, S., Marsden, C. D., Jenner, P. & Teychenne, P.) (Raven, New York, in the press).

  16. Garnett, E. S., Nahmias, C. & Firnau, G. Can. J. neurol. Sci. 11, 174–179 (1984).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Calne, D., Langston, J., Martin, W. et al. Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature 317, 246–248 (1985). https://doi.org/10.1038/317246a0

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/317246a0

This article is cited by

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing